Hongchang International Co., Ltd — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Hongchang International Co., Ltd filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.87M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $2.68M | Mar 28, 2025 |
| FY2022 | Dec 31, 2022 | $79.0K | Jun 22, 2023 |
| FY2022 | Dec 31, 2021 | $96.5K | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | $222.7K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $163.7K | Apr 1, 2022 |
| FY2016 | Dec 31, 2016 | $188.2K | Dec 7, 2017 |
| FY2016 | Sep 30, 2016 | $188.2K | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | $41.7K | Dec 7, 2017 |
| FY2016 | Mar 31, 2016 | $146.5K | Dec 7, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $181.6K | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $69.4K | Mar 28, 2025 |
| FY2022 | Dec 31, 2022 | $51.6K | Jun 22, 2023 |
| FY2022 | Dec 31, 2021 | $66.2K | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | $104.2K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $80.1K | Apr 1, 2022 |
| FY2016 | Dec 31, 2016 | $118.3K | Dec 7, 2017 |
| FY2016 | Sep 30, 2016 | ($70) | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | $24.2K | Dec 7, 2017 |
| FY2016 | Mar 31, 2016 | $94.2K | Dec 7, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($378.8K) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($240.0K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($163.0K) | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | ($548.4K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($488.4K) | Apr 1, 2022 |
| FY2019 | Dec 31, 2018 | ($250.3K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($54.1K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($158.5K) | Jan 26, 2018 |
| FY2016 | Sep 30, 2016 | ($109.5K) | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | $54.1K | Dec 7, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($383.3K) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | ($469.6K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($240.0K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($162.8K) | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | ($278.8K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($538.1K) | Apr 1, 2022 |
| FY2019 | Dec 31, 2018 | ($247.8K) | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | ($54.1K) | Jan 26, 2018 |
| FY2016 | Dec 31, 2016 | ($287.9K) | Dec 7, 2017 |
| FY2016 | Sep 30, 2016 | ($113.6K) | Dec 7, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $54.2K | Dec 7, 2017 |
| FY2016 | Sep 30, 2016 | $2.5K | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | $15.2K | Dec 7, 2017 |
| FY2016 | Mar 31, 2016 | $36.5K | Dec 7, 2017 |
| FY2016 | Dec 31, 2015 | $214.9K | Dec 7, 2017 |
| FY2016 | Sep 30, 2015 | $53.7K | Dec 7, 2017 |
| FY2016 | Jun 30, 2015 | $53.1K | Dec 7, 2017 |
| FY2016 | Mar 31, 2015 | $54.5K | Dec 7, 2017 |
| FY2014 | Dec 31, 2014 | $225.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $236.3K | Mar 31, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($7.34M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $750.5K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($225.8K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($141.1K) | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | ($21.8K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($546.6K) | Apr 1, 2022 |
| FY2019 | Dec 31, 2018 | ($265.3K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($41.3K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($308.0K) | Jan 26, 2018 |
| FY2016 | Sep 30, 2016 | ($213.7K) | Dec 7, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.02M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $40.60M | Mar 28, 2025 |
| FY2014 | Dec 31, 2014 | $9.6K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $4.7K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $2.2K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $2.3K | Apr 1, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $57.45M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $50.22M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $31.24M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $93.5K | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | $194.3K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $852.5K | Apr 1, 2022 |
| FY2019 | Dec 31, 2018 | $58.9K | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | $0 | Jan 26, 2018 |
| FY2016 | Sep 30, 2016 | $97.2K | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | $207.2K | Dec 7, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $18.68M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $9.73M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $31.66M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.90M | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.82M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.62M | Apr 1, 2022 |
| FY2019 | Dec 31, 2018 | $296.1K | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | $54.1K | Jan 26, 2018 |
| FY2016 | Sep 30, 2016 | $191.5K | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | $192.1K | Dec 7, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $38.77M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $40.49M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($418.7K) | Apr 1, 2024 |
| FY2023 | Dec 31, 2021 | ($193.8K) | Apr 1, 2024 |
| FY2021 | Dec 31, 2020 | ($1.40M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($715.9K) | Apr 1, 2022 |
| FY2019 | Dec 31, 2018 | ($237.2K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($54.1K) | Mar 28, 2019 |
| FY2014 | Dec 31, 2014 | $3.70M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $4.20M | Mar 31, 2015 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $1.95M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $1.95M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $1.95M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $1.95M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $1.95M | May 8, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.29M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | ($812.5K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($433.7K) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | ($19.62M) | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | ($19.46M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($18.91M) | Apr 1, 2022 |
| FY2019 | Dec 31, 2018 | ($18.42M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($18.17M) | Mar 28, 2019 |
| FY2014 | Dec 31, 2014 | ($14.42M) | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | ($13.92M) | Mar 31, 2015 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $895.7K | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $3.1K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.3K | Jun 22, 2023 |
| FY2019 | Dec 31, 2019 | $95.5K | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $37.6K | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | $0 | Jan 26, 2018 |
| FY2016 | Sep 30, 2016 | $97.2K | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | $192.0K | Dec 7, 2017 |
| FY2016 | Mar 31, 2016 | $59.2K | Dec 7, 2017 |
| FY2017 | Dec 31, 2015 | $178.2K | Jan 26, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.23M | Mar 28, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 1, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Jan 26, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Jan 26, 2018 |
| FY2016 | Sep 30, 2016 | 0 | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | 0 | Dec 7, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Jun 22, 2023 |
| FY2017 | Dec 31, 2017 | 0 | Jan 26, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Jan 26, 2018 |
| FY2016 | Sep 30, 2016 | 0 | Dec 7, 2017 |
| FY2016 | Jun 30, 2016 | 0 | Dec 7, 2017 |
| FY2016 | Mar 31, 2016 | 0 | Dec 7, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Dec 7, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 518.83M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | 518.83M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 415.58M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 1.03B | Jun 22, 2023 |
| FY2021 | Dec 31, 2020 | 1.03M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 1.03B | Apr 1, 2022 |
| FY2019 | Dec 31, 2018 | 1.14B | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 32.47M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 49.71M | Jan 26, 2018 |
| FY2016 | Dec 31, 2015 | 49.71M | Dec 7, 2017 |